Tag: Advanced Bifurcation Systems

Advanced Bifurcation Systems Inc. Receives FDA Breakthrough Device Designation

LIVERMORE, Calif., Oct. 23, 2023 /PRNewswire/ — Advanced Bifurcation Systems Inc. (ABS), a pioneer in comprehensive solutions for bifurcation lesions in coronary angioplasty, today announced that it has received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its novel coronary artery bifurcation stenting technology. This prestigious designation […]

Advanced Bifurcation Systems Announces First Closing Of Series A Financing

LIVERMORE, Calif., Dec. 16, 2020 /PRNewswire/ — Advanced Bifurcation Systems, Inc. (ABS), a Livermore, CA-based maker of the ABS System, a proprietary stent delivery system that is specifically designed to efficiently treat coronary bifurcation lesions, is pleased to announce the first closing of an $11 million Series A equity financing.  The round was led by […]

Advanced Bifurcation Systems Appoints Industry Veteran Thomas O’Neill to Board of Directors

LOS ANGELES, Jan. 25, 2018 (GLOBE NEWSWIRE) — Advanced Bifurcation Systems (“ABS” or the “Company”), a clinical stage medical device company developing an innovative stenting platform which overcomes the limitations of current approaches for the treatment of bifurcation lesions in coronary angioplasties, today announced the addition of Thomas O’Neill to the Board […]

Advanced Bifurcation Systems Announces Scott King Joins as Chief of Compliance Ahead of FDA Application

Published: Jan 05, 2018 Los Angeles –January 4, 2017 – Advanced Bifurcation Systems (ABS) Scott King has joined the leadership team as Vice President of Regulatory Affairs. ABS is a clinical stage, medical device company whose stenting platform overcomes the limitations of current approaches for the treatment of bifurcation lesions in coronary angioplasties […]

Advanced Bifurcation Systems Announces Plan for Human Clinical Trials in New Brunswick, Canada

LOS ANGELES, Oct. 03, 2017 (GLOBE NEWSWIRE) — Advanced Bifurcation Systems (“ABS” or the “Company”), a clinical stage medical device company developing an innovative stenting platform which overcomes the limitations of current approaches for the treatment of bifurcation lesions in coronary angioplasties, today announced that the Company is planning to […]